---
title: "Hong Kong Stock Movement: INSILICO approved by FDA but fell 11.58%, leading stocks in the life sciences sector under pressure"
description: "INSILICO fell 11.58%; Jingtao Holdings fell 6.23%, with a transaction volume of HKD 792 million; WuXi Biologics fell 3.36%, with a transaction volume of HKD 442 million; WuXi AppTec fell 0.96%, with a"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273643394.md"
published_at: "2026-01-26T03:37:25.000Z"
---

# Hong Kong Stock Movement: INSILICO approved by FDA but fell 11.58%, leading stocks in the life sciences sector under pressure

> INSILICO fell 11.58%; Jingtao Holdings fell 6.23%, with a transaction volume of HKD 792 million; WuXi Biologics fell 3.36%, with a transaction volume of HKD 442 million; WuXi AppTec fell 0.96%, with a transaction volume of HKD 323 million; WuXi Huilian fell 3.71%, with a market value of HKD 83.2 billion

**Hong Kong Stock Movement**

INSILICO fell by 11.58%. Based on recent key news:

1.  On January 23, INSILICO announced that its oral NLRP3 inhibitor ISM8969 for the treatment of inflammatory and neurodegenerative diseases received approval from the U.S. FDA for clinical trial applications. This news should have been positive, but the market reacted poorly, leading to a decline in stock price. Source: Zhitong Finance
    
2.  On January 23, the approval of INSILICO's ISM8969 clinical trial marked the company's strategic advancement in AI-driven drug discovery. However, investors remain cautious about its market prospects, affecting the stock price. Source: Reuters
    

**Stocks with High Trading Volume in the Industry**

JingTai Holdings fell by 6.23%, with a trading volume of HKD 792 million, and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

WuXi Biologics fell by 3.36%. Based on recent news:

1.  On January 26, WuXi Biologics recorded a cross-trade of 902,500 shares at a price of HKD 38.25 per share, down 2.7% from the previous closing price, leading to a decline in stock price. The transaction amount was HKD 292 million, with a net active sell of HKD 59.24 million.
    
2.  On January 23, WuXi AppTec and WuXi Biologics repeatedly reduced their holdings, cashing out over HKD 5 billion in total, raising market concerns and affecting investor confidence.
    
3.  On January 24, the foundation of WuXi's capital operation 2.0 version relies on market capitalization growth. If the industry experiences a downturn or geopolitical risks increase, a market cap correction will break the closed loop, affecting cash-out and reinvestment capabilities. WuXi Biologics still shows resilience in the mainland CRO/CDMO field.
    

WuXi AppTec fell by 0.96%. Based on recent key news:

1.  On January 26, WuXi AppTec made strategic adjustments, divesting non-core businesses to focus on its main operations and enhance profitability. The company is concentrating resources on the CRDMO core track by divesting its subsidiaries, Kangde Hongyi and WuXi Jinshi. Although this move improves performance, increased reliance on the U.S. market poses policy risks, affecting investor confidence.
    
2.  On January 24, WuXi AppTec's capital operation capabilities have matured, forming a full-track coverage capability, but the reduction in holdings has raised market concerns. Frequent cash-outs by the company may affect investor confidence, compounded by the impact of U.S. tax rates on income, with external uncertainties still present.
    
3.  On January 23, WuXi AppTec's market capitalization rose to approximately HKD 300 billion, with the actual controller cashing out over HKD 5 billion. Although this is a capital operation strategy, a decrease in R&D investment may affect technological iteration capabilities, leading to market concerns about long-term value. The CXO industry trend is favorable, with clear policy support.
    

**Stocks with High Market Capitalization in the Industry**

WuXi HeLian fell by 3.71%. Based on recent key news:

1.  On January 24, the new production line of WuXi HeLian faces uncertainties in construction cycles and ramp-up, affecting market confidence. The risks of capacity expansion and integration may lead to stock price volatility, especially during the integration process after acquiring DongYao Pharmaceutical
    
2.  On January 23rd, WuXi AppTec's actual controller reduced their shareholding, cashing out over 5 billion yuan, raising concerns among investors. Frequent share reductions may affect the market's confidence in the company's future development, leading to a decline in stock prices.
    
3.  On January 23rd, WuXi AppTec's R&D investment decreased by 13.7% year-on-year, with the R&D expense ratio dropping to 2.5%, weakening its technological iteration capability. The reduction in R&D investment may impact the company's long-term competitiveness, thereby affecting stock prices. The pharmaceutical industry faces policy and market challenges

### Related Stocks

- [03696.HK - INSILICO](https://longbridge.com/en/quote/03696.HK.md)
- [02228.HK - XTALPI](https://longbridge.com/en/quote/02228.HK.md)
- [02269.HK - WUXI BIO](https://longbridge.com/en/quote/02269.HK.md)
- [02359.HK - WUXI APPTEC](https://longbridge.com/en/quote/02359.HK.md)
- [02268.HK - WUXI XDC](https://longbridge.com/en/quote/02268.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts WuXi XDC Cayman's Price Target to HK$87.73 From HK$82.72, Keeps at Buy | Nomura Adjusts WuXi XDC Cayman's Price Target to HK$87.73 From HK$82.72, Keeps at Buy | [Link](https://longbridge.com/en/news/275736820.md) |
| BlackRock's long position in H-shares of Wuxi Apptec decreases to 4.51% on Feb 16 from 5.22%, HKEX shows | BlackRock's long position in H-shares of Wuxi Apptec decreases to 4.51% on Feb 16 from 5.22%, HKEX shows | [Link](https://longbridge.com/en/news/276436772.md) |
| Insilico Medicine Unveils AI-Designed ISM5059 as Preclinical NLRP3 Inhibitor Candidate | Insilico Medicine Cayman Topco has nominated ISM5059, an AI-designed small molecule inhibitor targeting NLRP3, as a prec | [Link](https://longbridge.com/en/news/274977240.md) |
| Insilico Medicine nominiert ISM5059 als neuen NLRP3-Hemmer für Entzündungstherapien | Insilico Medicine Cayman Topco has nominated ISM5059 as a preclinical candidate. ISM5059 is an AI-driven, peripherally a | [Link](https://longbridge.com/en/news/274977231.md) |
| InSilico Medicine Doses First Patient in ISM5411 Study | InSilico Medicine Doses First Patient in ISM5411 Study | [Link](https://longbridge.com/en/news/272203151.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
